ManitobaRSVProphylaxisProgramPast,PresentandFutur.ppt

ManitobaRSV Prophylaxis Program: Past, Present and Future Aaron Chiu Section of Neonatology Department of Paediatrics University of Manitoba Questions for consideration Who should be given palivizumab? Why are we giving palivizumab? What is the cost? Objectives Review RSV – burden of disease, later disease Review palivizumab Eligibility Criteria Program: how it works Regional challenges Outreach program 2005-06 Program statistics Manitoba approach to 33-35 wks infants 2006-07 Program and Eligibility Criteria Disclosure Abbott Canada provides Yearly funding to run the program Funds for nursing staff to run clinics No part of funding from Abbott goes to physician remuneration No physician remuneration from MB Health I do not directly hold shares in Abbott Quiz Which of the following is true? Infection with RSV confers immunity for the rest of the season Immunization with palivizumab decreases likelihood of becoming infected with RSV Palivizumab, like RSV-IVIG is contraindicated in infants with congenital heart disease A single dose of palivizumab is sufficient to provide immunity for the next month Answer Which of the following is true? Infection with RSV confers immunity for the rest of the season Immunization with palivizumab decreases likelihood of becoming infected with RSV Palivizumab, like RSV-IVIG is contraindicated in infants with congenital heart disease A single dose of palivizumab is sufficient to provide immunity for the next month RSV Most common cause of LRTI in young children Infection does not result in immunity Re-infection common Common presentation bronchiolitis Burden of RSV Illnesses Wheezing later Morbidity and Mortality Apnea Hospitalization – 1-2% require hospitalization Infants at risk significant RSV Preterm infants with BPD/CLD Children with other lung diseases Aboriginal Premature Infants Hemodynamically significant cardiac disease Pulmonary hypertension Children’s Hospital – RSV Burden Children’s Hospital – RSV Burden Immunoprophyl